
Brenig Therapeutics Unveils AI-Driven Strategy for Brain-Penetrant Drugs
Brenig Therapeutics is turning to artificial intelligence to bypass a long-standing hurdle in neurology: the difficulty of designing drugs that are both highly selective and capable of crossing the blood–brain barrier to treat neuroinflammatory conditions like Parkinson’s disease.


























